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Summary
Distal myopathy refers to a heterogeneous group of dis-
orders in which the initial manifestations are weakness
and atrophy of the hands and feet. We report a family
segregating an autosomal dominant distal myopathy,
with multiple affected individuals in whom vocal cord
and pharyngeal weakness may accompany the distal my-
opathy, without involvement of the ocular muscles. To
our knowledge, this pedigree displays a distinct distal
myopathy with the added features of pharyngeal and
vocal cord dysfunction (VCPDM) that has not been pre-
viously reported. We mapped the MPD2 gene for
VCPDM to chromosome 5q within a 12-cM linkage
interval between markers D5S458 and D5S1972 in a
large pedigree (a maximum LOD score of 12.94 at a
recombination fraction of 0 for D5S393) and combined
genome screening and DNA pooling successfully
adapted to fluorescent markers. This technique provides
for the possibility of fully automated genome scans.
Introduction
Distal myopathy refers to a heterogeneous group of dis-
orders in which the initial manifestations are weakness
and atrophy of the hands and feet (Griggs and Markes-
bery 1994). The inheritance can be dominant or reces-
sive, for both childhood- and adult-onset forms. In some
distal myopathies, the muscle biopsy may display a
rimmed vacuolar myopathy with trichrome stains. There
are some autosomal dominant distal myopathies that
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display inclusion bodies (Askanas and Engel 1998; Far-
deau and Tome 1998). We report a family segregating
an autosomal dominant distal myopathy, with multiple
affected individuals in whom vocal cord and pharyngeal
weakness may accompany the distal myopathy, without
involvement of the ocular muscles. This form of distal
myopathy has not been previously recognized and is dis-
tinct from other myopathies with pharyngeal or vocal
weakness. We localized the gene responsible for this
disorder to chromosome 5q31 by combining genome
screening and DNA-pooling strategies that use fluores-
cent microsatellite markers.
Family and Methods
Family Collection
The study was approved by the review board of the
Henry Ford Hospital. Informed consent was obtained
from family members.
DNA Isolation, Pooling, and Genotyping
DNA was isolated and purified from peripheral blood
by use of standard protocols. We adapted the DNA-
pooling genome-scanning method (Sheffield et al. 1994;
Carmi et al. 1995) to fluorescent markers. Two DNA
pools, one for the healthy individuals and one for the
affected members, were prepared. DNA concentration
was determined by optical density (OD) reading at 260
nm. DNA concentration was set to 100 mg/ml before
pooling. DNA quality and concentration were controlled
by PCR amplification. Each pool was made by the com-
bination of seven DNA samples. After pooling, DNA
concentration was checked to be ∼100 mg/ml by use of
OD reading. Because age at onset for the disease initially
appeared to be 35–57 years, the pool of healthy indi-
viduals was prepared with DNA from unaffected mem-
bers 157 years of age.
Genotyping was performed with fluorescent end-la-
beled microsatellite markers from the Ge´ne´thon map;
average spacing was 15 cM. PCR reactions were per-
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Figure 1 Pedigree of the initial branch of the kindred studied. Blackened circles and squares indicate members reported to be affected or
definitely affected, determined on the basis of neurological findings.
formed in 15 ml containing 20 ng genomic DNA, 0.33
mM each primer, 0.16 mM dNTPs, 10 mM Tris-HCl,
pH 9, 50 mM KCl, 1.5 mM MgCl2, 0.1% Triton, and
0.5 U Taq polymerase. DNA was denatured for 5 min
at 96C followed by 35 cycles of amplification (dena-
turation for 40 s at 94C, and annealing and elongation
for 30 s at 55C). After the last cycle of amplification,
ends were repaired by the incubation of the PCR prod-
ucts for 30 min at 37C, with 0.3 U T4 DNA polymerase.
PCR products were combined by series of 8–12, depen-
dent on fluorophore and expected allele size. Aliquots
were denatured for 5 min at 94C before being loaded
onto a 5% denaturing polyacrylamide gel (Vignal et al.
1993). Alleles were separated by electrophoresis per-
formed with 373 ABI sequencers. Genotyping data were
processed with GENOTYPER (ABI), GENSCAN (ABI),
and MARKSYN (Ge´ne´thon) softwares.
Statistical Analysis of Linkage Data
LOD-score analysis was computed by use of FAST-
LINK (Schaffer 1996), under a dominant mode of in-
heritance and isofrequent alleles. The frequency of the
disease allele was set to .0001. Age-dependent pene-
trance was evaluated by use of the affected members of
the family.
Haplotypes were constructed by use of GENE-
HUNTER (Kruglyak et al. 1996). Because of the size of
the family and computation time limits, the pedigree was
broken into overlapping subfamilies, to ensure fast and
consistent haplotype construction.
Results
Clinical Features
The family’s pedigree is shown in figure 1, and the
clinical features of 12 affected individuals are summa-
rized in table 1. The family is Caucasian and originates
from the vicinity of southeastern Tennessee. Twelve of
37 reportedly affected individuals were examined clin-
ically. An autosomal dominant inheritance is likely in
this four-generation pedigree. The typical age at onset
is 35–57 years (average 45.7 years). The muscle weak-
ness usually involves the feet and ankles first but may
start in the hands. In two individuals (V-13 and V-14),
voice change was the initial manifestation. Asymmetric
involvement at onset is very typical, but eventually a
symmetric distal weakness of the hands and legs prevails.
The weakness in the legs often has a peroneal distri-
bution, but it eventually involves inversion of the ankle,
rendering the gait very unstable. The gastrocnemius
muscle is usually relatively spared. The use of ankle-foot
orthotic braces and/or canes may become necessary, but
ambulation is generally preserved. In the hands, the pat-
tern of weakness is very characteristic. The extensors of
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Table 1
Clinical Features of 12 Affected Individuals in the Kindred
Individual
Current Age
(years)
Age at Onset
(years) Sex Distal Weakness
Shoulder
Weakness
Swallowing or Vocal
Dysfunction CPK (# Normal)
IV-2 56 45 M L leg* 1 R
R hand  L
R 1 L  2 (45)
IV-4 48 44 M R hand* 1 L
R leg  L
R  WNL (45)
IV-6 65 57 M L leg* 1 R )  WNL
IV-12 50 45 M R leg* 1 L
R hand 1 L
)  1.3 (45)
IV-52 60 48 M R leg* 1 L
L hand 1 R
) ) 2
IV-38 72 54 F Hands*
Legs
R 1 L  WNL
V-12 51 40 M Legs*
R hand  L
)  2
V-13 42 41 M R leg  L
R hand
) * 2
V-14 58 52 F Hands  legs ) * )
V-17 52 35 M L leg* 1 R
R hand  L
R  L ) 2
V-18 50 35 M R leg* 1 L ) ) 8
V-19 47 47 F Hands
Legs
)  WNL
NOTE.—An asterisk (*) indicates the first symptom. CPK values are listed in relation to the upper limits of normal for the particular
laboratory. If the CPK value was obtained at an age differing from the current age, then that age (in years) is given in parentheses.
WNL  within normal limits.
the fingers are each affected to a varying degree. If the
hand is placed on a table, some fingers can be lifted
whereas others cannot. The variable weakness affects
the position of the fingers differently when the patient
is asked to extend the fingers and wrist (Brooke 1986).
The initial weakness in the hand also selectively involves
the abductor pollicis brevis, which is often strikingly
atrophied but without other symptoms of median nerve
entrapment.
The vocal cord and pharyngeal weakness can be pres-
ent at the onset of the distal-extremity weakness. At first,
the voice has a hypophonic, breathy quality, but this
may slowly progress to a wet, gurgling, hoarse voice
with hypernasal resonance and difficulty with swallow-
ing and aspiration. Activities such as gargling become
impossible. In some cases, laryngoscopy reveals bowing
of the vocal cords, with secretions constantly flowing
past as a result of incomplete closure of the glottis and
pharyngeal muscle weakness. The vocal cords can be
voluntarily opened but will never close properly. Aspi-
ration may be reduced by the injection of agents that
add bulk and act as stiffeners (teflon, gel foam, or fat)
or by bilateral silastic-implant medializations of the vo-
cal folds. Vocal cord dysfunction or swallowing disorder
was present in 9 of 12 affected individuals and was re-
ported to have occured in most of the affected deceased
relatives, at older ages.
Shoulder weakness was the only proximal muscle in-
volvement noted. The weakness was usually asymmetric
and predominantly affected the deltoid. Four of 12 in-
dividuals had shoulder weakness. Progressive external
ophthalmoplegia was not found. Significant ptosis was
not noted, except in one individual (IV-38) who reported
ptosis requiring corrective surgery at age 43 years. One
patient (V-12) was oxygen-dependent with restrictive
pulmonary disease and left-ventricular dysfunction with
ejection fraction of 45%. One patient (IV-50) was re-
ported to have cardiomyopathy together with coronary
artery disease. Frank unexplained cardiomyopathy was
not observed.
Electrodiagnostic and Muscle Biopsy Studies
Electromyographic (EMG) and nerve conduction–
velocity (NCV) data were available for 7 of 12 individ-
uals (table 2). The compound–muscle action potentials
in limb muscles could be either myopathic or neuro-
pathic. In 3 of 7 individuals, the NCV was mildly or
borderline slow. Electrodiagnostic studies of the vocal
and pharyngeal muscles in two individuals (IV-6 and IV-
12) showed myopathic potentials (table 3).
Muscle biopsy was performed on 6 of 12 individuals.
Patient IV-6 had quadriceps and gastrocnemius biopsies
that disclosed a chronic noninflammatory myopathy
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Table 2
EMG, NCV, and Muscle-Biopsy Data on Seven Affected
Members of the First Branch of the Kindred
Individual EMG NCV Muscle Biopsy
IV-2 Myopathy Normal Rimmed vacuoles,
central nuclei
IV-6 Distal
denervation
Normal Rimmed vacuoles,
atrophy
IV-38 Myopathy Borderline
slow
End-stage
myopathy
IV-52 Neuropathy Slow )
V-12 Myopathy Slow Rimmed vacuoles,
thin myelin
V-13 Neuropathy ) Rimmed vacuoles,
central nuclei
V-14 Myopathy Normal Rimmed vacuoles,
central nuclei
Table 3
EMG Study Results on Vocal and Pharyngeal Muscles of Two
Affected Members
Muscle IV-6 IV-12
Palatopharyngeus Myopathic Myopathic
Cricothyroideus Normal Normal
Strapedius Normal Normal
Vocalis Myopathic Myopathic
Cricopharyngeal Myopathic Myopathic
with the presence of characteristic, usually subsarcolem-
mal, rimmed vacuoles. In addition, there were atrophic
fibers consistent with denervation. The pathologic
changes were scant in the quadriceps and severe in the
gastrocnemius. Individual V-13 had a gastrocnemius bi-
opsy that demonstrated a slight to moderate noninflam-
matory myopathy with rimmed vacuoles and that also
had occasional atrophic fibers suggestive of denervation.
Ultrastructural studies of subject showed sparse, small
tubular aggregates close to the triads and occasionally
associated with minute myelinoid figures. In these bi-
opsies (IV-6 and V-13) thorough enzyme histochemical
(NADH, succinate dehydrogenase/phenazine metholsul-
fonate, cytochrome C oxydase, nonspecific esterase, al-
kaline phosphatase, and ATPase at pHs 9.4, 4.6, and
4.3) and ultrastructural (two grids per case) studies failed
to demonstrate mitochondrial abnormalities, amyloid
deposits (Congo red), or filamentous inclusions. In a
third patient (V-14), light (H and E, trichrome, NADH,
and ATPase) and electron-microscopy studies of a biopsy
from an unspecified muscle disclosed a mild, noninflam-
matory myopathy with rimmed vacuoles; the muscle was
devoid of sarcoplasmic or intranuclear inclusions, am-
yloid deposits (thioflavin T), or filamentous inclusions
(Tome and Fardeau 1994). The muscle biopsies of two
other individuals (IV-2 and IV-12) were reported to show
that of rimmed vacuoles, and a third subject (IV-38)
showed end-stage myopathy. One individual (V-12) un-
derwent a sural nerve biopsy in which thinned myelin
sheaths were reported.
Creatine phosphokinase (CPK) serum levels were gen-
erally within twice the upper limits of normal (table 1).
No values above twice-normal were encountered in
younger unaffected but at-risk members of the family.
These findings are probably related to the slow pro-
gression of the disease and to the relatively small mass
of muscle involved.
DNA Pooling with Fluorescent Markers
At first, linkage to the oculopharyngeal muscular dys-
trophy (OPMD; MIM 164300) locus on 14q was ex-
cluded by use of the two closest flanking markers (data
not shown; Brais et al. 1998). As a result, to map the
distal myopathy with the vocal cord and pharyngeal
weakness (VCPDM) gene a genomewide search was un-
dertaken at Ge´ne´thon. To reduce the genotyping effort,
the genome scan was done by means of DNA pooling
(Sheffield et al. 1994; Carmi et al. 1995). We adapted
this strategy to fluorescent markers. Several recessive dis-
orders have been successfully mapped by DNA pooling
in consanguineous families. To date, only one domi-
nantly inherited disease has been localized by use of such
a strategy (Brugada et al. 1997). In this approach, the
implicit hypothesis of a founder effect and a skewed
marker-allele distribution between the affected- and
healthy-individual DNA pools is anticipated for markers
in the vicinity of the disease gene. This approach fitted
perfectly the analysis of our large pedigree. Although in
recessive disorders homozygosity by descent inherited
from a common ancestor is expected at the disease locus,
in this case we expected skewing of a single allele.
A DNA pool was prepared by the combination of the
DNA from seven affected members. A control DNA pool
was comprised from seven healthy individuals. Because
the age at disease onset is 35–57 years, the pool of
healthy individuals was prepared by selection of the old-
est unaffected members of the family. Pools were geno-
typed with fluorescent end-labeled microsatellite mark-
ers from the Ge´ne´thon map (Weissenbach et al. 1992;
Dib et al. 1996). Average spacing was 15 cM. The ge-
nome scan demonstrated that two markers, D5S393 and
D5S410, located on the long arm of chromosome 5 and
separated by 21 cM, showed a marked difference in
allele distribution between the two pools. These findings
suggested possible linkage (fig. 2). The most dramatic
effect was observed for D5S393. The 170-bp allele was
almost totally absent from the “healthy” DNA pool,
whereas it was quite frequent in the “affected” DNA
pool. Likewise, the representation of the 162-bp allele
was increased in the “healthy” DNA pool and decreased
in the “affected” DNA pool. Although not as striking
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Figure 2 Allele frequency and distribution for DNA markers on
5q. DNA pools were prepared by the combination of DNA from seven
affected members (“affected DNA pool”) and from the oldest unaf-
fected members (“healthy DNA pool”) of the family. Pools were gen-
otyped with fluorescent end-labeled microsatellite markers from the
Ge´ne´thon map, on an ABI 373. Average spacing is 15 cM. The allele
sizes (in bp) are indicated below the peaks. Fluorescence intensity was
measured at the peaks by use of the ladder on the right. Table 4
Two-Point Linkage Analysis Data, Determined by Use of an
Autosomal Dominant Model with Age-Dependent Penetrance and
Even Marker-Allele Frequencies
RECOMBINATION FRACTION AT v 
MARKER .00 .1 .2 .3 .4 Zmax vmax
D5S1995 6.12 7.95 6.17 4.08 1.90 8.69 .026
D5S458 7.42 5.98 4.32 2.54 .82 7.42 .000
D5S393 12.94 10.74 8.23 5.46 2.54 12.94 .000
D5S479 10.73 8.81 6.64 4.29 1.89 10.73 .000
D5S414 10.52 8.66 6.49 4.10 1.64 10.52 .000
D5S500 8.79 7.37 5.66 3.75 1.76 8.79 .000
D5S658 8.70 7.57 5.94 3.99 1.87 8.69 .000
D5S2011 6.17 4.91 3.55 2.17 .92 6.17 .000
D5S2017 5.29 4.31 3.15 1.94 .83 5.29 .000
D5S1972 5.18 4.59 3.53 2.26 .99 5.18 .000
D5S436 5.29 6.05 5.11 3.53 1.67 6.09 .081
D5S638 6.88 2.71 2.45 1.70 .80 2.73 .117
D5S2090 10.54 3.27 2.92 1.95 .81 3.29 .116
D5S410 22.93 .46 1.24 1.01 .45 1.24 .212
NOTE.—LOD scores were computed by FASTLINK (Schaffer 1996),
under a dominant mode of inheritance and even allele frequencies.
The frequency of the disease allele was set to .0001. The age-dependent
penetrance plot was constructed mainly from the patients examined
and on the basis of information from other neurologists’ reports and
from what appeared to be reliable family memories of the onset of
the disease in their affected close relatives now deceased.
as that for D5S393, a skewed distribution between both
pools for the 309- and 311-bp alleles of D5S410 was
also observed. This study suggested that the VCPDM
gene might be located between these two markers.
Two-Point Linkage Analysis
The 12 affected members of the initial family were
genotyped for D5S393 and D5S410. Linkage was eval-
uated by the LOD-score method. Two-point linkage
analysis was performed under a dominant model. Evi-
dence of linkage was obtained for D5S393 with a max-
imum LOD score (Zmax) of 5.16 at a recombination frac-
tion (v) of .05. D5S410 gave a LOD score of 0.6 at
. These results were consistent with the poolingv  .3
data.
During this study, one member of the family identified
another, new branch, descended from the sister of I-1
(fig. 1). This branch contains seven living affected mem-
bers from whom DNA was obtained. These new mem-
bers were genotyped for 14 markers, including D5S393
and D5S410, in accordance with a standard protocol
(Vignal et al. 1993). Two markers were located proximal
to D5S393, and 10 markers spanned the 21-cM region
between D5S393 and D5S410. Two-point linkage anal-
ysis was performed under a dominant model with age-
dependent penetrance and isofrequent alleles (table 4).
Results confirmed linkage, with atZ  12.94 v max
for D5S393, by use of isofrequent alleles ( )..0 f  .09
This LOD score was very close to the expected LOD
score (12.98 at ) obtained by linkage simulationsv  .00
for a marker with five isofrequent alleles (Ott 1989;
Weeks et al. 1990). Because the LOD score depends on
the allele frequency, we varied the allele frequency for
the allele present on the disease haplotype, while keeping
the other alleles isofrequent. By use of frequencies of .01
and .3, LOD scores of 15.85 and 8.99, respectively, were
obtained.
Fine Mapping of the VCPDM Gene
Fine mapping of the VCPDM gene was undertaken
by haplotype construction and identification of recom-
binant haplotypes, by use of genotyping data for the 14
markers that span the region of interest (fig. 3). A total
of 21 affected individuals were studied, and several re-
combinant haplotypes were identified. Results from four
affected individuals, each of whom represent a class of
recombinant haplotypes, are presented in figure 4. The
centromeric recombination point was defined by
D5S1995 for member V-37. The telomeric recombina-
tion point was defined by D5S436 for member V-14.
Fi
gu
re
3
H
ap
lo
ty
pe
s
of
14
D
N
A
m
ar
ke
rs
on
5q
in
af
fe
ct
ed
m
em
be
rs
fr
om
bo
th
br
an
ch
es
of
th
e
ki
nd
re
d.
D
N
A
sa
m
pl
es
us
ed
in
th
e
D
N
A
-p
oo
lin
g
st
ra
te
gy
ar
e
in
di
ca
te
d
by
ti
ny
bl
ac
ke
ne
d
sq
ua
re
s
ne
xt
to
th
e
m
em
be
r
nu
m
be
r.
H
ap
lo
ty
pe
s
w
er
e
in
fe
rr
ed
by
us
e
of
G
E
N
E
H
U
N
T
E
R
(K
ru
gl
ya
k
et
al
.1
99
6)
.R
ec
on
st
ru
ct
ed
ha
pl
ot
yp
es
ar
e
in
it
al
ic
ty
pe
.T
o
en
su
re
fa
st
an
d
co
ns
is
te
nt
ha
pl
ot
yp
e
co
ns
tr
uc
ti
on
,
th
e
pe
di
gr
ee
w
as
br
ok
en
in
to
ov
er
la
pp
in
g
su
bf
am
ili
es
.
T
he
di
se
as
e
ha
pl
ot
yp
e
is
ci
rc
le
d.
1738 Am. J. Hum. Genet. 63:1732–1742, 1998
Figure 4 Illustration of the haplotypes of one unaffected and
four affected individuals, depicting recombination regions. Schematic
representation of the chromosomes shows specific recombination
events relevant to the localization of theMPD2 gene. Fourteen markers
are shown; the order is based on the Ge´ne´thon linkage map. The
unaffected (UA) and the affected (IV-6, V-37, V-18, and V-14) members
were used to define the smallest linkage interval and are indicated
above the haplotype. Circles indicate informative meioses. Parental
alleles segregating with the disease or the normal allele are represented,
by blackened or unblackened circles respectively. Horizontal bars in-
dicate uninformative meioses.
Figure 5 Schematic representation of chromosome 5q31 area
linked to the MPD2 locus. Distance between markers is indicated in
centimorgans, in accordance with the Ge´ne´thon linkage map. Cyto-
genetic location is based on the Human Gene Map.
However, D5S1972 and the two proximal markers,
D5S2011 and D5S2017, were not informative, and the
recombination may have occurred anywhere between
D5S658 and any of these three markers. To better map
the recombination point, two additional markers located
within this interval were typed but turned out to be
uninformative (data not shown). On the basis of the
results from the affected members, the chromosomal re-
gion linked to the VCPDM gene was determined to be
between markers D5S436 and D5S1995 and to span a
12-cM region (fig. 5).
A 49-year-old healthy member (UA) carried a recom-
binant disease haplotype (fig. 4). If this individual carried
the disease haplotype, UA would have a 70% chance of
the disease being evident at this age. The negative ex-
amination suggested the presence of a preferential lo-
cation of the disease gene, within the D5S1995–D5S658
linkage interval.
Discussion
We mapped the gene for VCPDM to chromosome 5q,
within a 12-cM linkage interval between markers
D5S458 and D5S1972 by genome screening using the
DNA-pooling strategy in a large pedigree. Linkage to
this locus is supported by a at forZ  12.94 v  0max
marker D5S393 and by the presence of a shared disease
haplotype among all affected members. The potential
recombinant seen in one unaffected member of this fam-
ily (UA, fig. 4) suggests that the VCPDM gene maps
within the proximal part of the 12-cM interval. This
data inference is in agreement with the location sug-
gested by the confidence interval (not shown) calculated
under the assumption of isofrequent allele distribu-
tion. Altogether, this may restrict the interval to
D5S1995–D5S658, a 7-cM region.
DNA pooling has proved to be a very efficient and
successful way to map genes mainly for recessive dis-
orders in consanguineous families (Sheffield et al. 1994;
Carmi et al. 1995). One dominantly inherited disorder
(Brugada et al. 1997) was mapped by pooling, and feas-
ibility was assessed, by use of fluorescent markers, for
two diseases for which gene locations were known (Da-
mji et al. 1998). We successfully adapted this strategy
to fluorescent markers and showed its potential in com-
bining genome screening and DNA pooling. This tech-
nique provides for the possibility of fully automated ge-
nome scans. Slippage of the T4 DNA polymerase during
PCR amplification usually produces shorter artifactual
DNA fragments, which could interfere with allele read-
ing in DNA pools. In our situation, the allele found in
the DNA pool of the affected members, for D5S393,
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Table 5
List of Classical Distal Myopathies
Designation Inheritancea Key Clinical Features Gene Location
Welander myopathyb AD Late adult onset in hands Unknown
Tibial muscular dystrophyb AD Late adult onset in anterior tibial muscles 2q31c
Markesbery-Griggs AD Late adult onset in distal limbs, eventual proximal involvement Unknown
Miyoshi myopathy AR Early adult onset in gastrocnemius muscles 2p12 d
Nonaka myopathy AR Early adult onset in distal anterior leg muscles 9e
Distal myopathyf AD Onset at 4–25 years, in toe, ankle, finger extensors, neck flexors 14
VCPDMg AD Late adult onset in ankle or finger extensors; vocal/pharyngeal weakness 5q31g
NOTE.—From Griggs and Markesbery 1994.
a AD  autosomal dominant, and AR  autosomal recessive.
b Also see review chapters in Askanas et al. 1998.
c Haravuori et al. 1998.
d Bejaoui et al. 1995.
e Ikeuchi et al. 1997.
f Laing et al. 1995.
g This report.
had a size (170 bp) very distinct from that of all the
other alleles observed in the pool, and slippage did not
blur the result. Even for D5S410, the skewed distribution
between both pools concerning two alleles with a 2-bp
difference (309 bp and 311 bp) was quite visible. De-
convolution methods that mathematically remove PCR-
slippage artifacts (Perlin et al. 1995) could improve ge-
notyping accuracy, particularly in DNA pooling.
To our knowledge, this pedigree displays a distinct
form of VCPDM that has not been previously reported
(table 1). Inherited myopathies with important laryn-
geal/pharyngeal weakness include OPMD and oculo-
pharyngodistal myopathy (Tome and Fardeau 1994);
however, our patients did not have significant ptosis
(with one exception) or progressive external ophthal-
moparesis. Although proximal weakness is more com-
mon in OPMD, distal weakness has been reported in
both OPMD and oculopharyngodistal myopathy. The
disorder that we report can be distinguished from
OPMD by the lack of ocular-muscle involvement and
the absence of intranuclear filamentous inclusions on
electron microscopy of the three patients studied. Fur-
thermore, linkage studies exclude the 14q11 OPMD lo-
cus in our family. Oculopharyngodistal myopathy is
characterized by slowly progressive ptosis, ophthalmo-
paresis, dysphagia, and distal weakness (Fardeau and
Tome 1998). It is uncertain whether oculopharyngodis-
tal myopathy is a variant of OPMD with distal weakness
or a distinct myopathy. It is possible that our family
represents a variant of oculopharyngodistal myopathy
without the ocular involvement and with a later age at
onset. Additional linkage studies will help distinguish
these disorders.
From a histopathological standpoint, the lesion ob-
served in these individuals with a noninflammatory my-
opathy with rimmed vacuoles probably fits into the spec-
trum of the inclusion-body myopathies. Overall, the
myopathy was mild or moderate. In one patient, the
myopathy was very subtle in the quadriceps but mod-
erate to severe in the gastrocnemius, where it had a dys-
trophic pattern. A finding that was present in all spec-
imens was rimmed vacuoles, with a characteristic light
electron-microscopy appearance. In the three biopsies
studied ultrastructurally, questionable sarcoplasmic fil-
aments were observed in only one case. In these biopsies,
amyloid was not detected by histochemical stains. How-
ever, in a given case, filaments may be scant, and their
identification may be difficult. Furthermore, immuno-
histochemistry for b-amyloid or for paired helical fila-
ments was not performed on any of the biopsies. Al-
though morphologically this rimmed vacuolar myopathy
cannot be separated from the Swedish, Finnish, and
other autosomal dominant inclusion-body myopathies
(Askanas and Engel 1998), its characteristic distal/vocal
cord/pharyngeal involvement and genetic abnormality
indicate that it is a separate clinicopathologic entity.
The autosomal dominant distal myopathies are a het-
erogeneous group of disorders that tentatively can be
classified by age at onset and by the characteristic that
muscles typically are involved first (table 5). More recent
linkage studies have helped to further distinguish these
disorders (table 5). The phenotype that we describe dif-
fers from the other autosomal dominant distal myopa-
thies in that the weakness can start in the hands, feet,
or voice/pharynx. The weakness in the hands involves
the finger extensors and abductor pollicis brevis muscles,
which is different from the thumb and index-finger
weakness of the Scandinavian form of distal myopathy.
The neck flexors were not involved in our patients (both
clinically and with electrodiagnostic testing), even when
there was severe vocal and pharyngeal weakness; this
differs from the patients of Laing et al. (1995), who had
MPD1 distal myopathy. In addition, the weakness does
not remain confined to the ankle extensors, as in tibial
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muscular dystrophy. The assignment of this disorder to
a locus on chromosome 5q also distinguishes this dis-
order from other forms of dominantly inherited distal
myopathy. In keeping with the precedent started by
Laing et al. (1995), the gene on 5q for this form of distal
myopathy is designated “MPD2.”
The phenotype that we describe in this family closely
resembles that reported by Young and Harper (1980) as
an autosomal dominant distal atrophy with vocal cord
paralysis. In the family reported by Young and Harper,
EMGs were obtained for two of nine affected individuals
and showed spontaneous fibrillation and either “reduced
interference pattern” or “reduced volitional activity.”
Muscle biopsies were not obtained. In our family, both
neurogenic and myopathic muscle potentials were ob-
served. Thus, we cannot exclude the possibility that the
phenotype reported by Young and Harper (1980) as a
distal atrophy with vocal cord paralysis was possibly a
distal myopathy instead. Linkage studies of the families
reported by Young and Harper (1980) may clarify this
issue. The MPD2 phenotype is also easily confused with
the neuronal form of Charcot-Marie-Tooth disease if the
EMG results for an individual patient suggest a neuro-
genic disorder with normal conduction velocities. The
diagnosis of VCPDM does not require voice and pha-
ryngeal changes, since some affected individuals in our
kindred did not show these changes at the time of their
examinations. Attention to the presentation and subse-
quent course in other family members is important. Mus-
cle biopsies that include an involved distal muscle and
examinations of other affected members of the family
are recommended.
Two diseases have been mapped to this chromosomal
region: an autosomal recessive (LGMD2F; MIM
601287) and an autosomal dominant (LGMD1A; MIM
15900) limb-girdle muscular dystrophy. LGMD2F has
been mapped to chromosome 5q33-34 (Passos-Bueno et
al. 1996) and is a result of a mutation in the d-sarcog-
lycan gene (Nigro et al. 1996). This gene is telomeric to
the linkage interval we defined and is therefore excluded.
LGMD1A has been mapped within a 2.5-Mb interval
flanked by D5S479 and D5S594 (Bartoloni et al. 1997).
Our linkage interval encompasses the LGMD1A locus;
however, both disorders are clinically quite different. The
proximal weakness in LGMD1A is always much more
severe than the distal weakness; the opposite is observed
in VCPDM. Age at onset is earlier in LGMD1A, and
anticipation is also suspected (Speer et al. 1998). In con-
trast, there is no evidence of anticipation in VCPDM.
Both diseases could actually be caused by distinct mu-
tations affecting either the same gene or syntenic genes.
At this point, these hypotheses cannot be resolved. It
should be remembered that both studies were based on
the examination of a single large family that represents
a founder effect and in which a single pathogenic mu-
tation is segregating. Hence, it is difficult at this stage
to generalize the clinical description to other mutations
within these genes. It will be of interest to review the
clinical properties once other independent VCPDM and
LGMD1A families have been identified. A similar situ-
ation has been observed for LGMD2B (LGMD2B; MIM
253601) and the distal Miyoshi type of muscular dys-
trophy (ARDMD; MIM 254130), which both mapped
to chromosome 2p (Bashir et al. 1994; Bejaoui et al.
1995). Recent results have shown that both diseases seg-
regated in the same family, which suggests that they were
both a result of the same allele (Illarioshkin et al. 1996;
Weiler et al. 1996).
The protein coded by the autosomal dominant gene
for VCPDM is unknown but is presumed to be expressed
in skeletal muscle. A search of the Human Gene Map
database for the D5S1995–D5S658 linkage interval re-
vealed 161 expressed sequence tags (ESTs) with no
known function in most instances. Among the ESTs with
a putative or known function, one (locus HSRNASMAP;
European Molecular Biology Library accession number
X87613) codes for a putative transcription factor that
contains a bromodomain highly expressed in skeletal
muscle (Nielsen et al. 1996). This gene is located be-
tween D5S393 and D5S500 and represents a potential
candidate gene. An autosomal dominant form of pro-
gressive hearing loss (DFNA15; MIM 602459) results
from an 8-bp deletion in the transcription factor
POU4F3 (Vahava et al. 1998). POU4F3 is located on
chromosome 5q31 telomeric to the VCPDM linkage in-
terval. In OPMD, the trinucleotide (GCG)8–13, coding for
a polyalanine tract is amplified in the poly(A)-binding
protein 2 gene (PABP2) on chromosome 14q. The
PABP2 protein is highly expressed in the nuclei of skel-
etal-muscle fibers (Brais et al. 1998). HSRNASMAP
therefore represents a good candidate gene for VCPDM.
Its possible role in VCPDM is presently being in-
vestigated.
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